

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL No. 2724
Case No. 2:16-MD-2724

THIS DOCUMENT RELATES TO:

Direct Purchaser Class Plaintiffs' Actions

HON. CYNTHIA M. RUGE

**AMENDED DECLARATION OF ERIC J. MILLER REGARDING
(A) DISSEMINATION OF THE NOTICE AND (B) REPORT ON REQUESTS
FOR EXCLUSION AND OBJECTIONS, IF ANY, RECEIVED TO DATE**

I, Eric J. Miller, hereby declare and state as follows:

1. I am a Senior Vice President with A.B. Data, Ltd. ("A.B. Data"). I am fully familiar with the facts contained herein based upon my personal knowledge, and if called as a witness, could and would testify competently thereto. I submit this amended declaration at the request of Settlement Class Counsel in connection with the above-captioned action (the "Action").

2. A.B. Data was appointed by the Court in its Order dated May 11, 2022: (1) Certifying a Settlement Class; (2) Granting Preliminary Approval of Settlement Agreements; (3) Appointing Settlement Class Counsel; (4) Appointing a Claims Administrator and Escrow Agent; (5) Approving the Form and Manner of Notice to the Settlement Class; (6) Preliminarily Approving the Form and Manner of Notice to the Settlement Class; and (7) Scheduling a Fairness Hearing (the "Preliminary Approval Order") to serve as claims administrator for the direct purchaser class settlements in this case. ECF No. 2093. A.B. Data's duties in this case include administering the distribution of notice of the settlement to class members. I am

submitting this declaration to advise the Court of A.B. Data's activities concerning distribution of notice and the results.

Direct Mail Notice

3. A.B. Data obtained from Settlement Class Counsel a listing of 697 potential Settlement Class members developed from a number of sources, including transactional data produced by the defendants in discovery. Settlement Class Counsel performed research to locate mailing addresses for these potential Settlement Class members. Where a potential Settlement Class member had multiple locations, each of the addresses was captured and included in the mailing database. In addition, A.B. Data supplemented the list with additional mailing addresses through review of A.B. Data's own records from other direct purchaser pharmaceutical appointments and further independent research.

4. As a result of these efforts, A.B. Data obtained the identity and office addresses of 680 potential Settlement Class members and a total of 1,624 mailing addresses for the 680 entities. A.B. Data and Settlement Class Counsel were not able to locate a mailing address for the remaining 17 potential Settlement Class members because the potential Settlement Class members were no longer in business or the name of the entity was incomplete so the actual entity could not be located.

5. On June 24, 2022, A.B. Data arranged for the mailing of the Long Form Notice (the "Notice") to all 680 potential Settlement Class members. The Notice was also mailed to the additional addresses for certain Settlement Class

members. On the same day, A.B. Data posted the Notice on www.GenericDrugsDirectPurchaserSettlement.com, the website created for this litigation. A copy of the Notice is attached hereto as **Exhibit A**.

6. In sum, A.B. Data caused 1,585 Notices to be mailed to potential Settlement Class members. If all mailings to a potential Settlement Class member were returned as undeliverable as addressed by the United States Postal Service, A.B. Data performed additional research to locate an updated address or determine if the potential Settlement Class member was no longer in existence. Where an updated address was located, A.B. Data promptly remailed the Notice to the updated address.

7. On August 17, 2022, A.B. Data received from Settlement Class Counsel a listing of 62 additional potential Settlement Class member with 168 mailing addresses. A.B. Data loaded these records to the mailing database. On August 26, 2022, A.B. mailed a copy of the Notice to each of the 168 addresses included in the additional mailing list.

Media Notice

8. To supplement direct notice efforts, beginning on June 24, 2022, A.B. Data caused digital banner ads to appear on The Pink Sheet website for a period of 30 days. The Pink Sheet reaches over 3,000 of the world's leading pharmaceutical, contract research organizations (CROs), medical technology, biotechnology and healthcare service providers, including the top 50 global pharma and top 10 CROs. These ads appeared on both desktop and mobile formats. 39,997 impressions have

been delivered through the conclusion of the media notice on July 21, 2022. A sample of the digital banner and newsfeed ads are attached as **Exhibit B**.

9. A.B. Data also caused the Short Form Notice to be published in *The Wall Street Journal* on June 24, 2022. A copy is attached hereto as **Exhibit C**.

News Media

10. On June 24, 2022, A.B. Data disseminated a news release via Business Wire to announce the Settlements. This news release distributed via Business Wire went to the news desks of approximately 10,000 newsrooms, including those of print, broadcast, and digital websites across the United States. A copy of the news release is attached as **Exhibit D**.

Website and Telephone

11. To assist potential Settlement Class members in understanding the terms of the Settlements and their rights, A.B. Data established a case-specific toll-free telephone number (877-315-0583), email address (info@GenericDrugsDirectPurchaserSettlement.com), and a case-specific website (www.GenericDrugsDirectPurchaserSettlement.com).

12. On June 24, 2022, A.B. Data established a case-specific toll-free telephone number with an interactive voice response (“IVR”) system which provided summary information to frequently asked questions. This also provided callers the opportunity to speak with a live customer support representative. In addition, A.B. Data has received emails to the email address established for this matter.

13. On June 24, 2022, A.B. Data established a case-specific website, www.GenericDrugsDirectPurchaserSettlement.com. The website address appeared on the Notice and the newswire. The website includes case-specific information, including relevant deadlines and downloadable versions of the Notice, Settlement Agreements, Preliminary Approval Order, and other relevant documents. To date, the website has had 747 visitors.

14. On August 10, 2022, A.B. Data received copies of the: (1) Proposed Order Granting Motion for Order Pursuant to Paragraph 26 of the Court's May 11, 2022 Order; (2) Declaration of Dianne M. Nast in Support of Motion for Order Pursuant to Paragraph 26 of the Court's May 21, 2022 Order; (3) Exhibit 1 to Motion for an Order Pursuant to Paragraph 26 of the Court's May 11, 2022 Order; (4) Memorandum of Law in Support of Motion for an Order Pursuant to Paragraph 26 of the Court's May 11, 2022 Order; and (5) Motion for Order Pursuant to Paragraph 26 of the Court's May 11, 2022 Order. A.B. Data posted these documents to the case-specific website the same day.

15. On September 14, 2022, the Court entered an Order Extending the Deadline to Object to or Request Exclusion from the Sun and Taro Settlement Class and Rescheduling the Fairness Hearing (the "September Order"). On September 16, 2022, A.B. Data posted the September Order along with an update advising visitors of the updated objection and exclusion deadlines and the rescheduled Fairness Hearing date and time.

Requests for Exclusion and Objections

16. The Court's September Order required any Settlement Class member requesting exclusion from the Settlement Class to postmark such a request on or before January 10, 2023. As of the date of this Declaration, A.B. Data has received copies of ten requests for exclusion on behalf of 371 entities, many of which may not be direct purchasers (only 33 of the 371 entities seeking exclusion were identified as potential Settlement Class Members based on Defendants' transactional data).

17. Seven of the ten letters came from counsel for Direct Action Plaintiffs and seek the exclusion of 224 entities that appear to be subsidiaries and affiliates of 10 different Direct Action Plaintiffs. However, only 30 of these 224 Direct Action Plaintiff entities were identified as potential Settlement Class Members based on Defendants' transactional data.

18. The remaining three letters identified 147 entities that appear to be hospital systems, healthcare centers, and retail pharmacies. However, only three of these 147 entities were identified as potential Settlement Class Members based on Defendants' transactional data. Therefore, based on Defendants' transactional data, it appears that only 33 of 759 potential Settlement Class Members have requested to opt-out, and the bulk of those are Direct Action Plaintiffs that I understand have brought individual claims. Annexed hereto as **Exhibit E** is a list of the entities which have requested exclusion from the Settlement although many of them may not be direct purchasers from a defendant as indicated thereon.

19. Under the Court's September Order, the postmark deadline for a Settlement Class member to object to the settlement was January 10, 2023. The Notice directs members of the Settlement Class to mail their objection to Clerk of the United States District Court for the Eastern District of Pennsylvania with copies to Settlement Class Counsel and Settling Defendants' Counsel. As of the date of this Declaration, A.B. Data has not been notified of any objections.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on March 1, 2023.



Eric J. Miller

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

**If you purchased one or more of the
Named Generic Drugs listed in Appendix A
to this Notice directly from any of the
pharmaceutical manufacturer Defendants
listed in Appendix B to this Notice at any
time from May 1, 2009 until December
31, 2019, you could get a payment from a
class action settlement.**

A federal court authorized this Notice. This is not a solicitation from a lawyer.

The purpose of this Notice is to alert you of two proposed settlements in a Lawsuit brought by Direct Purchasers (“Settling Direct Purchaser Plaintiffs” or “DPPs”) of certain generic drugs (the “Named Generic Drugs”). The Lawsuit is a group of direct purchaser class actions coordinated under the civil docket *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.). The Lawsuit claims that generic drug manufacturers violated antitrust laws, harming competition and causing Settlement Class Members to overpay for the Named Generic Drugs. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. No trial has been held or scheduled.

- Two settlements have been reached between the DPPs and the Settling Defendants: (1) a proposed settlement with Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc.; and (2) a proposed settlement with Taro Pharmaceuticals U.S.A., Inc. (together, the “Settlements”). Settling Defendants are alleged to have violated the antitrust laws relating to the sale of the Named Generic Drugs. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing. The Named Generic Drugs are listed in Appendix A and the Defendants are listed in Appendix B.
- The Court has certified a Settlement Class comprised of:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.

- The Court has preliminarily approved the proposed Settlements between the Settling Direct Purchaser Plaintiffs and Settling Defendants. To resolve the DPPs' claims against Settling Defendants, the proposed Settlements will provide for the following payments by Settling Defendants: (1) \$17,357,000 payment by Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc. and URL Pharma, Inc. and (2) \$67,643,000 payment by Taro Pharmaceuticals U.S.A., Inc. These payments, collectively \$85,000,000, will comprise the "Settlement Fund." The Settlement Fund may be reduced by up to \$10 million or increased to a maximum of \$105 million under certain circumstances as explained in the Settlement Agreements. As discussed below, attorneys' fees, expenses, and service awards may be deducted from these amounts with Court approval, and after deduction of attorneys' fees, expenses and service awards, the remaining amount of the Settlement Fund is referred to as the "Net Settlement Fund".
- The Court has scheduled a hearing to decide whether to approve the Settlements, the plan for allocating the Net Settlement Fund to Settlement Class Members, any requests by the attorneys for reimbursement of expenses out of the Settlement Fund, payment of service awards to the Settling Direct Purchaser Plaintiffs, and any request to hold a portion of the Settlement Fund in escrow for potential payment of attorneys' fees at a later date, with Court approval (the "Final Fairness Hearing"). The Final Fairness Hearing is scheduled for December 13, 2022, at 1:30 p.m. EST, before Judge Cynthia M. Rufe at the United States District Court for the Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.

YOUR LEGAL RIGHTS ARE AFFECTED WHETHER YOU ACT OR DO NOT ACT,
SO PLEASE READ THIS NOTICE CAREFULLY.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
WHEN YOU RECEIVE A CLAIM FORM, PROMPTLY COMPLETE AND RETURN IT	<p>You do not need to do anything now to retain your right to stay in the Settlement Class and/or seek a share of the proposed Settlements. If the Court decides to give the proposed Settlements Final Approval and you are a Settlement Class Member, then you will need to complete, sign, and return a Claim Form to obtain a share of the proposed Settlements.</p> <p>If you received a Notice in the mail, a Claim Form will be mailed to you at a later date. While we anticipate using Defendants' sales data to show eligible purchases, if such information or data is not available from Defendants, you may be asked to provide information or data showing your eligible purchases.</p> <p>If you <u>did not</u> receive a Notice in the mail and you think you are a potential Settlement Class Member, please identify yourself by letter or email to the following addresses: <i>In re: Generic Pharmaceuticals Pricing Antitrust Litigation</i> – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217.</p> <p>Email: info@GenericDrugsDirectPurchaserSettlement.com</p> <p>You may be asked to provide information or data proving that you are a member of the Settlement Class. You also may be asked to provide data showing your eligible purchases if such data is not available from Defendants.</p>
EXCLUDE YOURSELF FROM THE SETTLEMENT CLASS	<p>You may choose to exclude yourself, or "opt out," from the Settlement Class. If you decide to exclude yourself, you will not be bound by any decision in this Lawsuit relating to the Settling Defendants. This is the only option that allows you to ever be part of any lawsuit (other than this Lawsuit) against the Settling Defendants relating to the legal claims against the Settling Defendants in this case. Copies of your election to exclude yourself must be sent to counsel listed in Section 13.</p>
STAY IN THE LAWSUIT BUT OBJECT TO THE SETTLEMENTS	<p>If you object to all or any part of the proposed Settlements, you may write to the Court about why you do not like the proposed Settlements. Copies of your objection must be sent to counsel listed in Section 13.</p>
GET MORE INFORMATION	<p>If you would like to obtain more information about the Lawsuit or the Settlements, you can send questions to the lawyers or Claims Administrator identified in this Notice and/or attend the hearing at which time the Court will evaluate the proposed Settlements.</p>

These rights and options – and the deadlines to exercise them – are explained in this Notice.

TABLE OF CONTENTS

WHAT THIS NOTICE CONTAINS

BASIC INFORMATION	PAGE 5
1. Why did I get this Notice?	
2. What is this Lawsuit about?	
3. What is a class action?	
4. Why are there Settlements?	
WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENTS.....	PAGE 6
5. Am I part of the Settlement Class and the Settlements?	
6. Can I request to be excluded from the Settlement Class?	
7. What happens if I do nothing?	
THE SETTLEMENTS' BENEFITS	PAGE 8
8. What do the Settlements provide?	
9. How can I get a payment from the Settlements?	
10. When would I get my payment and how much would it be?	
THE LAWYERS REPRESENTING THE SETTLEMENT CLASS	PAGE 10
11. Do I have a lawyer in this case?	
12. How will the lawyers be paid?	
OBJECTING TO THE SETTLEMENTS	PAGE 11
13. How do I tell the Court that I don't like the Settlements?	
THE COURT'S FAIRNESS HEARING	PAGE 12
14. When will the Court decide whether to approve the Settlements?	
15. Do I have to attend the hearing?	
16. May I speak at the hearing?	
GETTING MORE INFORMATION	PAGE 13
17. How do I get more information?	

BASIC INFORMATION

1. WHY DID I GET THIS NOTICE?

You received this Notice because, according to available data and documents, you may have purchased one or more Named Generic Drugs directly from one or more generic manufacturer Defendants listed on Appendix B, at some time from May 1, 2009 until December 31, 2019, and therefore you may be a member of the Settlement Class that was certified by the Court for purposes of the proposed Settlements. You may have received this Notice in error so you should confirm from your own records that you purchased one or more Named Generic Drugs directly from one or more generic manufacturer Defendants at some time from May 1, 2009 to December 31, 2019.

2. WHAT IS THIS LAWSUIT ABOUT?

The Lawsuit is a group of proposed class actions coordinated under the docket *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724. Judge Cynthia M. Rufe, of the United States District Court for the Eastern District of Pennsylvania (the “Court”), is overseeing the Lawsuit and the Settlements.

The Settling Direct Purchaser Plaintiffs allege that Defendants engaged in an unlawful scheme or schemes to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocation of the Named Generic Drugs in violation of federal antitrust laws. DPPs allege that this harmed competition and caused Settlement Class Members to overpay for the Named Generic Drugs.

All Defendants, including the Settling Defendants, deny that any Settlement Class Member is entitled to damages or other relief. All Defendants, including the Settling Defendants, deny liability as to DPPs’ claims. The Settlements between Settling Direct Purchaser Plaintiffs and the Settling Defendants are not admissions of wrongdoing by any Defendant, including the Settling Defendants.

Following investigation of relevant facts, substantial fact discovery, and following arms’-length negotiations with the Settling Defendants, the Settling Direct Purchaser Plaintiffs, on behalf of the Settlement Class, entered into the Settlements with the Settling Defendants.

There has been no determination by the Court or a jury that the allegations against the Defendants or Settling Defendants have been proven or that, if proven, the conduct caused harm to any Settlement Class Members. No trial has been held or scheduled.

3. WHAT IS A CLASS ACTION?

In a class action, one or more people or entities called “Class Representatives” (in this case, César Castillo, LLC, FWK Holdings, LLC, Rochester Drug Cooperative, Inc., and KPH Healthcare Services, Inc.) sue on behalf of others who have similar claims (collectively, the “DPPs” or the “Settling Direct Purchaser Plaintiffs”).

The DPPs and the entities on whose behalf they have sued together constitute the “Settlement Class” or “Settlement Class Members.” Their attorneys are called “Settlement Class Counsel.”

The companies that have been sued are called the “Defendants.” In this case the Defendants are the 58 companies listed at the end of this Notice, in Appendix B.

In a class action lawsuit, one court resolves the issues for all Class Members, except for those who exclude themselves (*i.e.*, “opt out”) from the Class. The Court, by order dated May 11, 2022, has determined that the Lawsuit between DPPs and the Settling Defendants can proceed as a class action for purposes of the proposed Settlements. A copy of the Court’s order may be found at GenericDrugsDirectPurchaserSettlement.com.

Specifically, the Court has found that:

- The number of Settlement Class Members is so numerous that joining them all into one suit is impracticable.
- Members of the Settlement Class share common legal or factual issues relating to the claims in this case.
- The claims of the DPPs are typical of the claims of the rest of the Settlement Class.
- The DPPs will fairly and adequately protect the interests of the Settlement Class.
- The common legal questions and facts predominate over questions affecting only individual members of the Settlement Class, and this Lawsuit will be more efficient than individual lawsuits.

4. WHY ARE THERE SETTLEMENTS?

The Court has not decided in favor of the Settling Direct Purchaser Plaintiffs or Settling Defendants. Instead, both sides have agreed to the Settlements. Settling Direct Purchaser Plaintiffs and the Settling Defendants were preparing to proceed with the litigation and eventually go to trial, but they have now agreed to the proposed Settlements. By agreeing to the Settlements, the parties avoid the costs and uncertainty of additional discovery, motion practice, and an eventual trial, and if the Settlements are approved by the Court, Settlement Class Members will be eligible to receive a payment from the Settlements. The Settlements do not mean that any law was broken or that the Settling Defendants did anything wrong. The DPPs and Settlement Class Counsel believe that the proposed Settlements are fair, reasonable, and adequate and in the best interests of the Settlement Class.

WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENTS

5. AM I PART OF THE SETTLEMENT CLASS AND THE SETTLEMENTS?

You are part of the Settlement Class if you are a person or entity in the United States and its territories that purchased one or more Named Generic Drugs directly from one or more Defendants at any time from May 1, 2009 until December 31, 2019.

More specifically, on May 11, 2022, the Court certified the following Settlement Class:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.

The Named Generic Drugs and Defendants are listed at the end of this Notice, in Appendices A and B.

If you are not sure whether you are included in the Settlement Class, you may call or write to the lawyers in this case at the telephone numbers or addresses listed in Question 11 below. If you wish to exclude yourself from the Settlement Class, please refer to Question 6.

6. CAN I REQUEST TO BE EXCLUDED FROM THE SETTLEMENT CLASS?

Yes, the Court has set a deadline for requests for exclusion of September 23, 2022. To exclude yourself, you must send a letter via First-Class U.S. Mail saying you want to exclude yourself from the Direct Purchaser Lawsuit in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.).

Mail the letter to: Lead Counsel for Plaintiffs and counsel for Settling Defendants listed in Section 13 of this Notice.

Be sure to include your name, address, email address, telephone number, and your signature. Your letter requesting exclusion must be postmarked no later than September 23, 2022.

If you exclude yourself from the Settlement Class, you will not be legally bound by anything that happens in the Lawsuit between DPPs and the Settling Defendants, and you may be able to sue (or continue to sue) the Settling Defendants in the future about the legal issues in this case. If you exclude yourself from the Settlement Class so that you can start or continue your own lawsuit against the Settling Defendants, you should talk to your own lawyer immediately because your claims will be subject to a statute of limitations, which means that your claims may expire if you do not take timely action. You need to contact your own lawyer about this issue.

If you do not exclude yourself from the Settlement Class, and you have a valid claim, you can share in the Settlements, but you will not be able to start a lawsuit, continue a lawsuit, or be part of any other lawsuit against the Settling Defendants arising from the claims released as part of these Settlements, including claims brought in the case between DPPs and the Settling Defendants. All of the Court's orders in the case between DPPs and the Settling Defendants will apply to you and legally bind you. You will also be bound by the proposed Settlements between DPPs and the Settling Defendants if the Court grants Final Approval to the proposed Settlements and enters final judgment in the case between the DPPs and the Settling Defendants.

7. WHAT HAPPENS IF I DO NOTHING?

If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlements as described in this Notice, if the Settlements are approved. **However, you will need to complete, sign, and return the Claim Form (once it is sent to you) in order to obtain a payment.** It is anticipated that Defendants' sales data will be used to calculate Settlement Class Members' eligible purchases and *pro rata* share of the Net Settlement Fund, but if such data is not available from Defendants, then you may be asked to submit data showing your eligible purchases. The date when the Claim Forms will be mailed has not yet been determined. You may check GenericDrugsDirectPurchaserSettlement.com for information regarding timing. At a later date, the settlement website will also have a blank Claim Form available to download.

THE SETTLEMENT BENEFITS

8. WHAT DO THE SETTLEMENTS PROVIDE?

The Settling Defendants have agreed to pay a total of \$85,000,000 in cash (which may be reduced to \$75,000,000 or increased to as much as \$105,000,000 under certain circumstances as explained in the Settlements) to an interest-bearing escrow account (“Settlement Fund”) for the benefit of the Settlement Class. This will come in the form of a \$17,357,000 payment from Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc. and URL Pharma, Inc.; and a \$67,643,000 payment from Taro Pharmaceuticals U.S.A., Inc. The Settlement Fund shall be held in escrow pending finality of the Settlement Agreements. The Settling Defendants also agreed to provide substantial cooperation to the DPPs in the continued litigation against the remaining Defendants.

Settlement Class Counsel will apply to the Court no later than August 9, 2022, for reimbursement of past expenses and for future expenses not to exceed a total of \$6.8 million, and service awards to the four Settling Direct Purchaser Plaintiffs of \$20,000 each for their substantial services to the Settlement Class. The Settlements also provide for payment from the Settlement Fund of up to \$500,000 in total (included within the \$6.8 million figure) for the costs of giving notice to Settlement Class members and administering the Settlements and making distributions from the fund. In addition, Settlement Class Counsel will ask the Court to set aside up to one-third of the remaining Settlement Fund after any Court awarded reimbursed expenses, notice and settlement administration costs, and service awards to Settling Direct Purchaser Plaintiffs (plus accrued interest) for payment of attorneys’ fees. Settlement Class Counsel will file a motion for an award of fees at a later appropriate time. For purposes of the objection and opt-out deadline of September 23, 2022, Settlement Class Members should assume that Settlement Class Counsel will seek attorneys’ fees of up to one-third of what remains in the Settlement Fund after any Court-awarded reimbursed expenses, notice and settlement administration costs, and service awards to Settling Direct Purchaser Plaintiffs are deducted. Settlement Class Members will have the opportunity to review, and object to, Settlement Class Counsel’s motion for attorneys’ fees after it is filed and before the Court rules. All motions for expenses, attorneys’ fees, and service awards shall be posted on the settlement website: GenericDrugsDirectPurchaserSettlement.com.

If approved by the Court, the Net Settlement Fund, including accrued interest, (the Settlement Fund minus any court-awarded attorneys’ fees, service awards and expenses) will be distributed to the Settlement Class Members who return valid and timely Claim Forms. The distribution will be made on a *pro rata* basis, consistent with each Settlement Class Member’s aggregate weighted share of total Settlement Class purchases of the Named Generic Drugs from Defendants. In the event that data from Defendants is not available to calculate a Settlement Class Member’s *pro rata* share, such Settlement Class Member will be required to submit data showing its relevant direct purchases as requested by the Claims Administrator. As a general matter, a claimant’s *pro rata* share will be based on data from Defendants, and claimants will not be permitted to submit their own purchase data to contest these figures. This is because of the time and expense that would be involved in analyzing such additional data (expenses that would be paid out of the Settlement Fund itself), and because transaction data from Defendants is considered reliable. More information about how Settlement Class Members’ shares will be calculated is available in the Plan of Allocation, on the settlement website: GenericDrugsDirectPurchaserSettlement.com.

In exchange, the litigation between the DPPs and the Settling Defendants will be dismissed with prejudice and Settling Defendants will be released by Settlement Class Members from all claims that have been brought or could have been brought concerning the subject matter of or acts, omissions, or other conduct alleged in Settling Direct Purchaser Plaintiffs’ class action complaints.

Non-Settling Defendants are not part of the proposed Settlements between the DPPs and the Settling Defendants. DPPs' Lawsuit against the Non-Settling Defendants is continuing.

The Settlement Agreements provide that they may be terminated if, for example, the Court does not approve the Settlements or if Settlement Class Members with aggregate purchases above a certain amount opt out. If the Settlement Agreements are terminated, the Lawsuit will proceed against the Settling Defendants as if Settlements had not been reached.

The full text of the Settlement Agreements, including the releases, are available at GenericDrugsDirectPurchaserSettlement.com. This Notice is not meant to, and does not, alter the terms of the actual Settlement Agreements and associated releases.

9. HOW CAN I GET A PAYMENT FROM THE SETTLEMENTS?

If the Court grants Final Approval to the Settlements (*see* "The Court's Fairness Hearing" below) and any resulting appeals are resolved, the Court will approve a Plan of Allocation to distribute the Settlement Fund.

If you do not exclude yourself from the Settlement Class, you will need to submit a Claim Form to request your share of the Net Settlement Fund.

- If you received this Notice in the mail, a Claim Form will be sent to you automatically and you do not need to do anything at this time to be eligible to receive a payment from the Settlements. However, while we anticipate using Defendants' sales data for eligible purchases, if such data is not available from Defendants you may be required to submit data showing your eligible purchases.
- If you did not receive this Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter or email to the following addresses: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217. Email: info@GenericDrugsDirectPurchaserSettlement.com. You must also include proof that you purchased at least one of the Named Generic Drugs during the period May 1, 2009 to December 31, 2019, directly from a Defendant. You may also be required to submit your purchase data showing all your eligible purchases if such data is not available from Defendants. At a later date when claim forms are mailed, a copy of the Claim Form will also be available at GenericDrugsDirectPurchaserSettlement.com.

10. WHEN WOULD I GET MY PAYMENT AND HOW MUCH WOULD IT BE?

When you get your payment depends on several matters, including whether and when the Court grants Final Approval of the Settlements. The Settlement Fund will be allocated to Settlement Class Members as soon as possible after the Court grants Final Approval of the Settlements.

You will not be responsible for calculating the amount you may be entitled to receive. The Plan of Allocation provides that you will be paid on a *pro rata* basis in proportion to how much of the Named Generic Drugs you purchased directly from Defendants from May 1, 2009 through December 31, 2019. Generally, those with more purchases will get a higher recovery. If less than 100% of the Settlement Class submit Claim Forms, you could get a larger *pro rata* share.

If the proposed Settlements are given Final Approval, but there is an appeal of the Final Approval, the appeal could take several years to resolve. Any accrued interest on the Settlement Fund will be included, *pro rata*, in the amount paid to Settlement Class Members.

If you exclude yourself from the Settlement Class, which means that you are choosing not to be a part of the Settlement Class and the Settlements, then you will not receive a share of the Net Settlement Fund.

THE LAWYERS REPRESENTING THE CLASS

11. DO I HAVE A LAWYER IN THIS CASE?

The Court appointed the counsel listed below as Settlement Class Counsel:

<p>Dianne M. Nast, Esq. Joseph N. Roda, Esq. NASTLAW LLC 1101 Market Street, Suite 2801 Philadelphia, PA 19107 (215) 923-9300 dnast@nastlaw.com jnroda@nastlaw.com Lead Counsel for Plaintiffs</p>	<p>David F. Sorensen, Esq. BERGER MONTAGUE PC 1818 Market Street, Suite 3600 Philadelphia, PA 19103 (215) 875-3000 dsorensen@bm.net</p>
<p>Robert N. Kaplan KAPLAN FOX & KILSHEIMER LLP 850 Third Avenue New York, NY 10022 (212) 687-1980 rkaplan@kaplanfox.com</p>	<p>Thomas M. Sobol, Esq. HAGENS BERMAN SOBOL SHAPIRO LLP 55 Cambridge Parkway, Suite 301 Cambridge, MA 02142 (617) 482-3700 tom@hbsslaw.com</p>
<p>Linda P. Nussbaum NUSSBAUM LAW GROUP, PC 1211 Avenue of the Americas, 40th Floor New York, NY 10036 (917) 438-9189 lnussbaum@nussbaumpc.com</p>	<p>Michael L. Roberts ROBERTS LAW FIRM P.A. 20 Rahling Circle Little Rock, AR 72223 (501) 821-5575 mikeroberts@robertslawfirm.us</p>

12. HOW WILL THE LAWYERS BE PAID?

The attorneys are not asking for fees at this time. However, they are asking that one-third of the Settlement Fund, after deduction of expenses and service awards, be held in escrow for a future fee application. Settlement Class Counsel will ask now as part of the Final Approval of these Settlements for reimbursement of expenses not to exceed a total of \$6.8 million for payment of past and future expenses, including costs of administering these Settlements plus service awards in the amount of \$20,000 for each of the four named plaintiffs. If you decide not to exclude yourself from the Settlement Class, you will not have to pay these fees, costs, and expenses out of your own pocket. If the Court grants Settlement Class Counsel's requests, these amounts would be deducted from the Settlement Fund.

Any application by Settlement Class Counsel for reimbursement of expenses, service awards to the DPPs, and to hold up to a third of the Settlement Fund (net of any Court approved expenses, administration costs, and service awards to the Direct Purchaser Settling Plaintiffs) in escrow

for potential payment of attorneys' fees at a later date will be filed with the Court and made available for download and/or viewing on or before August 9, 2022, on GenericDrugsDirectPurchaserSettlement.com, as well as at the office of the Clerk of the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106-1797, during normal business hours.

OBJECTING TO THE SETTLEMENTS

13. HOW DO I TELL THE COURT THAT I DON'T LIKE THE SETTLEMENTS?

If you are a Settlement Class Member (and have not excluded yourself), you can object to all or any part of the proposed Settlements and/or the application to hold up to one-third of the Settlement Fund in escrow for later payment of attorneys' fees, for reimbursement of costs and expenses, and/or service awards to the Class Representatives. You can give reasons why you think the Court should not approve it. The Court will consider your views.

To object to the Settlements, you must send a letter via First-Class U.S. Mail saying that you object to the Settlements in the Direct Purchaser Lawsuit in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.) with the following information:

- Your name, address, email address, and phone number, and the name, address, and phone number of your attorney, if you have one.
- Your signature.
- Case name and number:

In re: Generic Pharmaceuticals Pricing Antitrust Litigation
Case No. 2:16-MD-02724

United States District Court for the Eastern District of Pennsylvania

- The specific reasons why you object to the Settlements or any part of them.
- All documents or writings that you want the Court to consider.

Mail the objection to the Clerk of the United States District Court for the Eastern District of Pennsylvania (address below) with copies to the individuals and addresses listed below:

CLERK OF THE COURT	SETTLEMENT CLASS COUNSEL	SETTLING DEFENDANTS' COUNSEL
Clerk of Court, EDPA 601 Market Street Philadelphia, PA 19106	Dianne M. Nast Joseph N. Roda NastLaw LLC 1101 Market Street, Ste. 2801 Philadelphia, PA 19107 <i>Lead Counsel for Plaintiffs</i>	John Taladay Baker Botts L.L.P. 700 K Street, N.W. Washington, D.C. 20001

Your objection must be postmarked on or before September 23, 2022.

THE COURT'S FAIRNESS HEARING

The Court will hold a hearing to decide whether to grant Final Approval to the Settlements and any requests for reimbursement of expenses, service awards, and a set aside for a future application for attorneys' fees ("Fairness Hearing"). You may attend and, if you have not excluded yourself from the Settlement Class, you may ask to speak, but you do not have to speak.

14. WHEN WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENTS?

The Court has scheduled a Fairness Hearing on December 13, 2022, at 1:30 p.m. EST, at the United States District Court Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.

The time and date of the Fairness Hearing may change without additional mailed notice. A notification will be placed on the settlement website. For updated information on the hearing, check GenericDrugsDirectPurchaserSettlement.com, or the Court docket in this case (for a fee) through the Court's Public Access to Court Electronic Records (PACER) system at <https://pcl.uscourts.gov>.

At the Fairness Hearing, the Court will consider whether the Settlements are fair, reasonable, and adequate. The Court may also consider the requests by Settlement Class Counsel for a set aside for attorneys' fees, reimbursement of expenses, and payment of service awards. If there are objections, the Court will consider them at that time. After the hearing, the Court will decide whether to give Final Approval to the Settlements and the other requests. There is no specific date as to when these decisions will be issued.

Any judgment issued by the Court will be binding on the Settlement Class. The Settlements, if approved by the Court and once appeals, if any, are resolved, will release all claims of the Settlement Class in the class action against the Settling Defendants.

15. DO I HAVE TO ATTEND THE HEARING?

No. Settlement Class Counsel will answer any questions the Court may have. However, you are welcome to attend the hearing at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, to the proper addresses, and it complies with the other requirements provided above, the Court will consider it. You also may pay your own lawyer to attend the hearing, but this is not necessary. Attendance is not necessary to receive your share of the Net Settlement Fund, if the Court approves the proposed settlements.

16. MAY I SPEAK AT THE HEARING?

You may ask the Court for permission to speak at the Fairness Hearing. To do so, you must send a letter via First-Class U.S. Mail saying that it is your "Notice of Intention to Appear in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.)." Be sure to include your name, address, email address, telephone number, and your signature. Your Notice of Intention to Appear must be postmarked no later than September 23, 2022, and must be sent to the Clerk of the Court, to Settlement Class Counsel, and to Settling Defendants' Counsel at the addresses listed in Question 13 above.

You may not speak at the hearing if you excluded yourself as a Settlement Class Member or do not send a notice of intention to appear.

GETTING MORE INFORMATION

17. HOW DO I GET MORE INFORMATION?

If you have questions about this case or want additional information, you may call or write to the lawyers listed in answer to Question 11 above, call 877-315-0583, or visit GenericDrugsDirectPurchaserSettlement.com. This Notice is only a summary of the proposed Settlements and is qualified in its entirety by the terms of the Settlement Agreements. Copies of the Settlement Agreements are on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. The Settlement Agreements are also available on the settlement website: GenericDrugsDirectPurchaserSettlement.com. You may also call the Claims Administrator at 877-315-0583 with questions.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE TO INQUIRE ABOUT THE SETTLEMENTS OR THE CLAIMS PROCESS.

APPENDIX A: NAMED GENERIC DRUGS

Molecule Name	Form	Strength
1 ACETAZOLAMIDE	TABLET	125MG
1 ACETAZOLAMIDE	TABLET	250MG
1 ACETAZOLAMIDE ER	CAPSULE	500MG
2 ADAPALENE	CREAM	0.10%
2 ADAPALENE	GEL	0.10%
2 ADAPALENE	GEL	0.30%
3 ALBUTEROL	TABLET	2MG
3 ALBUTEROL	TABLET	4MG
4 ALCLOMETASONE DIPROPIONATE	CREAM	0.05%
4 ALCLOMETASONE DIPROPIONATE	OINTMENT	0.05%
5 ALLOPURINOL	TABLET	100MG
5 ALLOPURINOL	TABLET	300MG
6 AMANTADINE HCL	CAPSULE	100MG
7 AMILOLIDE HCL/HCTZ	TABLET	5MG;50MG
8 AMITRIPTYLINE	TABLET	100MG
8 AMITRIPTYLINE	TABLET	10MG
8 AMITRIPTYLINE	TABLET	150MG
8 AMITRIPTYLINE	TABLET	25MG
8 AMITRIPTYLINE	TABLET	50MG
8 AMITRIPTYLINE	TABLET	75MG
9 AMMONIUM LACTATE	CREAM	12%
9 AMMONIUM LACTATE	LOTION	12%
10 AMOXICILLIN/CLAVULANATE	TABLET CHEWABLE	200MG;28.5MG
10 AMOXICILLIN/CLAVULANATE	TABLET CHEWABLE	400MG;57MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	10MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	20MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	30MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	5MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	10MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	15MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	20MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	25MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	30MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	5MG
12 ATENOLOL/CHLORTHALIDONE	TABLET	100MG;25MG
12 ATENOLOL/CHLORTHALIDONE	TABLET	50MG;25MG
13 ATROPINE SULFATE	SOLUTION	1%
14 BACLOFEN	TABLET	10MG
14 BACLOFEN	TABLET	20MG
15 BALSALAZIDE DISODIUM	CAPSULE	750MG
16 BENAZEPRIL HCTZ	TABLET	10MG;12.5MG
16 BENAZEPRIL HCTZ	TABLET	20MG;12.5MG
16 BENAZEPRIL HCTZ	TABLET	20MG;25MG
17 BETAMETHASONE DIPROPIONATE	CREAM	0.05%
17 BETAMETHASONE DIPROPIONATE	LOTION	0.05%

17 BETAMETHASONE DIPROPIONATE	OINTMENT	0.05%
18 BETAMETHASONE DIPROPIONATE AUGMENTED	LOTION	0.05%
19 BETAMETHASONE DIPROPIONATE/CLOTRIMAZOLE	CREAM	0.05%;1%
19 BETAMETHASONE DIPROPIONATE/CLOTRIMAZOLE	LOTION	0.05%;1%
20 BETAMETHASONE VALERATE	CREAM	0.10%
20 BETAMETHASONE VALERATE	LOTION	0.10%
20 BETAMETHASONE VALERATE	OINTMENT	0.10%
21 BETHANECHOL CHLORIDE	TABLET	10MG
21 BETHANECHOL CHLORIDE	TABLET	25MG
21 BETHANECHOL CHLORIDE	TABLET	50MG
21 BETHANECHOL CHLORIDE	TABLET	5MG
22 BROMOCRIPTINE MESYLATE	TABLET	2.5MG
23 BUDESONIDE	SOLUTION	0.25MG/2ML
23 BUDESONIDE	SOLUTION	0.5MG/2ML
23 BUDESONIDE	SOLUTION	1MG/2ML
23 BUDESONIDE DR	CAPSULE	3MG
24 BUSPIRONE HCL	TABLET	10MG
24 BUSPIRONE HCL	TABLET	15MG
24 BUSPIRONE HCL	TABLET	30MG
24 BUSPIRONE HCL	TABLET	5MG
24 BUSPIRONE HCL	TABLET	7.5MG
25 BUTORPHANOL TARTRATE	SPRAY	10MG/ML
26 CAPECITABINE	TABLET	150MG
26 CAPECITABINE	TABLET	500MG
27 CAPTOPRIL	TABLET	100MG
27 CAPTOPRIL	TABLET	12.5MG
27 CAPTOPRIL	TABLET	25MG
27 CAPTOPRIL	TABLET	50MG
28 CARBAMAZEPINE	TABLET	200MG
28 CARBAMAZEPINE	TABLET CHEWABLE	100MG
28 CARBAMAZEPINE ER	TABLET	100MG
28 CARBAMAZEPINE ER	TABLET	200MG
28 CARBAMAZEPINE ER	TABLET	400MG
29 CARISOPRODOL	TABLET	350MG
30 CEFIDINIR	CAPSULE	300MG
30 CEFIDINIR	SOLUTION	125MG/5ML
30 CEFIDINIR	SOLUTION	250MG/5ML
31 CEFPROZIL	TABLET	250MG
31 CEFPROZIL	TABLET	500MG
32 CEFUROXIME AXETIL	TABLET	250MG
32 CEFUROXIME AXETIL	TABLET	500MG
33 CELECOXIB	CAPSULE	100MG
33 CELECOXIB	CAPSULE	200MG
33 CELECOXIB	CAPSULE	400MG
33 CELECOXIB	CAPSULE	50MG
34 CEPHALEXIN (CEFALEXIN)	SOLUTION	125MG/5ML
34 CEPHALEXIN (CEFALEXIN)	SOLUTION	250MG/5ML
35 CHLORPROMAZINE HCL	TABLET	100MG

35 CHLORPROMAZINE HCL	TABLET	10MG
35 CHLORPROMAZINE HCL	TABLET	200MG
35 CHLORPROMAZINE HCL	TABLET	25MG
35 CHLORPROMAZINE HCL	TABLET	50MG
36 COLESTYRAMINE	PACKET/ORAL SOLID	4G
36 COLESTYRAMINE	POWDER	4G
37 CICLOPIROX	CREAM	0.77%
37 CICLOPIROX	SHAMPOO	1%
37 CICLOPIROX	SOLUTION	8%
38 CIMETIDINE	TABLET	200MG
38 CIMETIDINE	TABLET	300MG
38 CIMETIDINE	TABLET	400MG
38 CIMETIDINE	TABLET	800MG
39 CLARITHROMYCIN ER	TABLET	500MG
40 CLINDAMYCIN PHOSPHATE	GEL	1%
40 CLINDAMYCIN PHOSPHATE	LOTION	1%
40 CLINDAMYCIN PHOSPHATE	SOLUTION	1%
40 CLINDAMYCIN PHOSPHATE	VAGINAL CREAM	2%
41 CLOBETASOL	CREAM	0.05%
41 CLOBETASOL	E CREAM	0.05%
41 CLOBETASOL	GEL	0.05%
41 CLOBETASOL	OINTMENT	0.05%
41 CLOBETASOL	SOLUTION	0.05%
42 CLOMIPRAMINE	CAPSULE	25MG
42 CLOMIPRAMINE	CAPSULE	50MG
42 CLOMIPRAMINE	CAPSULE	75MG
43 CLONIDINE ER	PATCH	0.1MG/24HR
43 CLONIDINE ER	PATCH	0.2MG/24HR
43 CLONIDINE ER	PATCH	0.3MG/24HR
44 CLOTRIMAZOLE	SOLUTION	1%
45 DESMOPRESSIN ACETATE	TABLET	0.1MG
45 DESMOPRESSIN ACETATE	TABLET	0.2MG
46 DESONIDE	CREAM	0.05%
46 DESONIDE	LOTION	0.05%
46 DESONIDE	OINTMENT	0.05%
47 DESOXIMETASONE	OINTMENT	0.25%
48 DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	15MG
48 DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	20MG
48 DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	40MG
48 DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	5MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	10MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	15MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	2.5MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	20MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	30MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	5MG
49 DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	7.5MG
49 DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	10MG

49 DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	15MG
49 DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	5MG
50 DICLOFENAC POTASSIUM	TABLET	50MG
51 DIGOXIN	TABLET	0.125MG
51 DIGOXIN	TABLET	0.25MG
52 DILTIAZEM HCL	TABLET	120MG
52 DILTIAZEM HCL	TABLET	30MG
52 DILTIAZEM HCL	TABLET	60MG
52 DILTIAZEM HCL	TABLET	90MG
53 DIPHENOXYLATE/ATROPINE	TABLET	2.5MG;0.025MG
54 DIVALPROEX ER	TABLET	250MG
54 DIVALPROEX ER	TABLET	500MG
55 DOXAZOSIN MESYLATE	TABLET	1MG
55 DOXAZOSIN MESYLATE	TABLET	2MG
55 DOXAZOSIN MESYLATE	TABLET	4MG
55 DOXAZOSIN MESYLATE	TABLET	8MG
56 DOXYCYCLINE HYCLATE	CAPSULE	100MG
56 DOXYCYCLINE HYCLATE	CAPSULE	50MG
56 DOXYCYCLINE HYCLATE	TABLET	100MG
56 DOXYCYCLINE HYCLATE DR	TABLET	100MG
56 DOXYCYCLINE HYCLATE DR	TABLET	150MG
56 DOXYCYCLINE HYCLATE DR	TABLET	75MG
56 DOXYCYCLINE MONOHYDRATE	TABLET	100MG
56 DOXYCYCLINE MONOHYDRATE	TABLET	150MG
56 DOXYCYCLINE MONOHYDRATE	TABLET	50MG
56 DOXYCYCLINE MONOHYDRATE	TABLET	75MG
57 DROSPIRENONE/ETHINYL ESTRADIOL (OCELLA)	TABLET	3MG-0.02MG
57 DROSPIRENONE/ETHINYL ESTRADIOL (OCELLA)	TABLET	3MG-0.03MG
58 ECONAZOLE	CREAM	1%
59 ENALAPRIL MALEATE	TABLET	10MG
59 ENALAPRIL MALEATE	TABLET	2.5MG
59 ENALAPRIL MALEATE	TABLET	20MG
59 ENALAPRIL MALEATE	TABLET	5MG
60 ENTECAVIR	TABLET	0.5MG
60 ENTECAVIR	TABLET	1MG
61 ESTRADIOL	TABLET	0.5MG
61 ESTRADIOL	TABLET	1MG
61 ESTRADIOL	TABLET	2MG
62 ESTRADIOL/NORETHINDRONE ACETATE (MIMVEY)	TABLET	1MG-0.5MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-0.1MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.15MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.15MG-.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-0.1MG-.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-.15MG;.025MG-.15MG;.03MG-.15MG;.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.05MG;.04MG-.075MG;.03MG-.125MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-.09MG
64 ETODOLAC	CAPSULE	200MG
64 ETODOLAC	CAPSULE	300MG

64 ETODOLAC	TABLET	400MG
64 ETODOLAC	TABLET	500MG
64 ETODOLAC ER	TABLET	400MG
64 ETODOLAC ER	TABLET	500MG
64 ETODOLAC ER	TABLET	600MG
65 EXEMESTANE	TABLET	25MG
66 FENOFIBRATE	TABLET	145MG
66 FENOFIBRATE	TABLET	48MG
67 FLUCONAZOLE	TABLET	100MG
67 FLUCONAZOLE	TABLET	150MG
67 FLUCONAZOLE	TABLET	200MG
67 FLUCONAZOLE	TABLET	50MG
68 FLUOCINOLONE ACETONIDE	CREAM	0.01%
68 FLUOCINOLONE ACETONIDE	CREAM	0.03%
68 FLUOCINOLONE ACETONIDE	OINTMENT	0.03%
68 FLUOCINOLONE ACETONIDE	SOLUTION	0.01%
69 FLUOCINONIDE	CREAM	0.05%
69 FLUOCINONIDE	CREAM	0.10%
69 FLUOCINONIDE	E CREAM	0.05%
69 FLUOCINONIDE	GEL	0.05%
69 FLUOCINONIDE	OINTMENT	0.05%
69 FLUOCINONIDE	SOLUTION	0.05%
70 FLUOXETINE HCL	TABLET	10MG
70 FLUOXETINE HCL	TABLET	15MG
70 FLUOXETINE HCL	TABLET	20MG
70 FLUOXETINE HCL	TABLET	60MG
71 FLUTICASONE PROPIONATE	SPRAY	50MCG
72 FOSINOPRIL HCTZ	TABLET	10MG;12.5MG
72 FOSINOPRIL HCTZ	TABLET	20MG;12.5MG
73 GABAPENTIN	TABLET	600MG
73 GABAPENTIN	TABLET	800MG
74 GLIMEPIRIDE	TABLET	1MG
74 GLIMEPIRIDE	TABLET	2MG
74 GLIMEPIRIDE	TABLET	4MG
75 GLIPIZIDE/METFORMIN	TABLET	2.5MG;250MG
75 GLIPIZIDE/METFORMIN	TABLET	2.5MG;500MG
75 GLIPIZIDE/METFORMIN	TABLET	5MG;500MG
76 GLYBURIDE	TABLET	1.25MG
76 GLYBURIDE	TABLET	2.5MG
76 GLYBURIDE	TABLET	5MG
77 GLYBURIDE/METFORMIN	TABLET	1.25MG;250MG
77 GLYBURIDE/METFORMIN	TABLET	2.5MG;500MG
77 GLYBURIDE/METFORMIN	TABLET	5MG;500MG
78 GRISEOFULVIN	SUSPENSION (MICROSIZE)	125MG/5ML
79 HALOBETASOL PROPIONATE	CREAM	0.05%
79 HALOBETASOL PROPIONATE	OINTMENT	0.05%
80 HALOPERIDOL	TABLET	0.5MG
80 HALOPERIDOL	TABLET	10MG

80 HALOPERIDOL	TABLET	1MG
80 HALOPERIDOL	TABLET	20MG
80 HALOPERIDOL	TABLET	2MG
80 HALOPERIDOL	TABLET	5MG
81 HYDROCODONE/ACETAMINOPHEN	TABLET	325MG;10MG
81 HYDROCODONE/ACETAMINOPHEN	TABLET	325MG;5MG
82 HYDROCORTISONE VALERATE	CREAM	0.20%
83 IRBESARTAN	TABLET	150MG
83 IRBESARTAN	TABLET	300MG
83 IRBESARTAN	TABLET	75MG
84 ISOSORBIDE DINITRATE	TABLET	10MG
84 ISOSORBIDE DINITRATE	TABLET	20MG
84 ISOSORBIDE DINITRATE	TABLET	30MG
84 ISOSORBIDE DINITRATE	TABLET	5MG
85 KETOCONAZOLE	CREAM	2%
85 KETOCONAZOLE	TABLET	200MG
86 KETOPROFEN	CAPSULE	50MG
86 KETOPROFEN	CAPSULE	75MG
87 KETOROLAC TROMETHAMINE	TABLET	10MG
88 LABETALOL HCL	TABLET	100MG
88 LABETALOL HCL	TABLET	200MG
88 LABETALOL HCL	TABLET	300MG
89 LAMIVUDINE/ZIDOVUDINE (COMBIVIR)	TABLET	150MG;300MG
89 LAMIVUDINE/ZIDOVUDINE (COMBIVIR)	TABLET	300MG;150MG
90 LATANOPROST	SOLUTION	0.01%
91 LEFLUNOMIDE	TABLET	10MG
91 LEFLUNOMIDE	TABLET	20MG
92 LEVOTHYROXINE	TABLET	0.025MG
92 LEVOTHYROXINE	TABLET	0.05MG
92 LEVOTHYROXINE	TABLET	0.075MG
92 LEVOTHYROXINE	TABLET	0.088MG
92 LEVOTHYROXINE	TABLET	0.112MG
92 LEVOTHYROXINE	TABLET	0.125MG
92 LEVOTHYROXINE	TABLET	0.137MG
92 LEVOTHYROXINE	TABLET	0.15MG
92 LEVOTHYROXINE	TABLET	0.175MG
92 LEVOTHYROXINE	TABLET	0.1MG
92 LEVOTHYROXINE	TABLET	0.2MG
92 LEVOTHYROXINE	TABLET	0.3MG
93 LIDOCAINE HCL	OINTMENT	5%
94 LIDOCAINE/PRILOCaine	CREAM	2.5%;2.5%
95 LOPERAMIDE HCL	CAPSULE	2MG
96 MEPROBAMATE	TABLET	200MG
96 MEPROBAMATE	TABLET	400MG
97 METFORMIN (F) ER	TABLET	1000MG
97 METFORMIN (F) ER	TABLET	500MG
98 METHADONE HCL	TABLET	10MG
98 METHADONE HCL	TABLET	5MG

99 METHAZOLAMIDE	TABLET	25MG
99 METHAZOLAMIDE	TABLET	50MG
100 METHOTREXATE	TABLET	2.5MG
101 METHYLPHENIDATE	TABLET	10MG
101 METHYLPHENIDATE	TABLET	20MG
101 METHYLPHENIDATE	TABLET	5MG
101 METHYLPHENIDATE ER	TABLET	20MG
102 METHYLPREDNISOLONE	TABLET	4MG
103 METRONIDAZOLE	CREAM	0.75%
103 METRONIDAZOLE	GEL	0.75%
103 METRONIDAZOLE	GEL	1%
103 METRONIDAZOLE	GEL VAGINAL	0.75%
103 METRONIDAZOLE	LOTION	0.75%
104 MOEXIPRIL HCL	TABLET	15MG
104 MOEXIPRIL HCL	TABLET	7.5MG
105 MOEXIPRIL HCL/HCTZ	TABLET	15MG;12.5MG
105 MOEXIPRIL HCL/HCTZ	TABLET	15MG;25MG
105 MOEXIPRIL HCL/HCTZ	TABLET	7.5MG;12.5MG
106 NADOLOL	TABLET	20MG
106 NADOLOL	TABLET	40MG
106 NADOLOL	TABLET	80MG
107 NAPROXEN SODIUM	TABLET	275MG
107 NAPROXEN SODIUM	TABLET	550MG
108 NEOMYCIN/POLYMYXIN/HYDROCORTISONE	SOLUTION	3.5MG;10MU;1%
109 NIACIN ER	TABLET	1000MG
109 NIACIN ER	TABLET	500MG
109 NIACIN ER	TABLET	750MG
110 NIMODIPINE	CAPSULE	30MG
111 NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	100MG
111 NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	25MG
111 NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	50MG
112 NORETHINDRONE/ETHINYL ESTRADIOL (BALZIVA)	TABLET	0.4MG-0.035MG
113 NORTRIPTYLINE HCL	CAPSULE	10MG
113 NORTRIPTYLINE HCL	CAPSULE	25MG
113 NORTRIPTYLINE HCL	CAPSULE	50MG
113 NORTRIPTYLINE HCL	CAPSULE	75MG
114 NYSTATIN	CREAM	100MU
114 NYSTATIN	OINTMENT	100MU
114 NYSTATIN	TABLET	500MU
115 NYSTATIN/TRIAMCINOLONE	CREAM	0.10%
115 NYSTATIN/TRIAMCINOLONE	OINTMENT	0.10%
116 OMEGA 3 ACID ETHYL ESTERS	CAPSULE	1G
117 OXaprozin	TABLET	600MG
118 OXYBUTYNIN CHLORIDE	TABLET	5MG
119 OXYCODONE/ACETAMINOPHEN	TABLET	10MG;325MG
119 OXYCODONE/ACETAMINOPHEN	TABLET	5MG;325MG
119 OXYCODONE/ACETAMINOPHEN	TABLET	7.5MG;325MG
120 OXYCODONE HCL	SOLUTION	20MG/ML

120 OXYCODONE HCL	TABLET	15MG
120 OXYCODONE HCL	TABLET	30MG
121 PARICALCITOL	CAPSULE	1MCG
121 PARICALCITOL	CAPSULE	2MCG
121 PARICALCITOL	CAPSULE	4MCG
122 PAROMOMYCIN	CAPSULE	250MG
123 PERMETHRIN	CREAM	5%
124 PERPHENAZINE	TABLET	16MG
124 PERPHENAZINE	TABLET	2MG
124 PERPHENAZINE	TABLET	4MG
124 PERPHENAZINE	TABLET	8MG
125 PHENYTOIN SODIUM ER	CAPSULE	100MG
126 PILOCARPINE HCL	TABLET	5MG
127 PIROXICAM	CAPSULE	10MG
127 PIROXICAM	CAPSULE	20MG
128 POTASSIUM CHLORIDE ER	TABLET	10MEQ
128 POTASSIUM CHLORIDE ER	TABLET	20MEQ
128 POTASSIUM CHLORIDE ER	TABLET	8MEQ
129 PRAVASTATIN	TABLET	10MG
129 PRAVASTATIN	TABLET	20MG
129 PRAVASTATIN	TABLET	40MG
129 PRAVASTATIN	TABLET	80MG
130 PRAZOSIN HCL	CAPSULE	1MG
130 PRAZOSIN HCL	CAPSULE	2MG
130 PRAZOSIN HCL	CAPSULE	5MG
131 PREDNISOLONE ACETATE	SOLUTION/LIQUID EYE	1%
132 PREDNISONE	TABLET	10MG
132 PREDNISONE	TABLET	1MG
132 PREDNISONE	TABLET	2.5MG
132 PREDNISONE	TABLET	20MG
132 PREDNISONE	TABLET	5MG
133 PROCHLORPERAZINE	SUPPOSITORY	25MG
134 PROMETHAZINE	SUPPOSITORY	12.5MG
134 PROMETHAZINE	SUPPOSITORY	25MG
135 PROPRANOLOL	TABLET	10MG
135 PROPRANOLOL	TABLET	20MG
135 PROPRANOLOL	TABLET	40MG
135 PROPRANOLOL	TABLET	60MG
135 PROPRANOLOL	TABLET	80MG
135 PROPRANOLOL ER	CAPSULE	120MG
135 PROPRANOLOL ER	CAPSULE	160MG
135 PROPRANOLOL ER	CAPSULE	60MG
135 PROPRANOLOL ER	CAPSULE	80MG
136 RALOXIFENE HCL	TABLET	60MG
137 RANITIDINE HCL	CAPSULE	150MG
137 RANITIDINE HCL	CAPSULE	300MG
137 RANITIDINE HCL	TABLET	150MG
138 SILVER SULFADIAZINE	CREAM	1%

139 SPIRONOLACTONE/HCTZ	TABLET	25MG;25MG
140 TACROLIMUS	OINTMENT	0.03%
140 TACROLIMUS	OINTMENT	0.10%
141 TAMOXIFEN CITRATE	TABLET	10MG
141 TAMOXIFEN CITRATE	TABLET	20MG
142 TEMOZOLOMIDE	CAPSULE	100MG
142 TEMOZOLOMIDE	CAPSULE	140MG
142 TEMOZOLOMIDE	CAPSULE	180MG
142 TEMOZOLOMIDE	CAPSULE	20MG
142 TEMOZOLOMIDE	CAPSULE	250MG
142 TEMOZOLOMIDE	CAPSULE	5MG
143 TERCONAZOLE	VAGINAL CREAM	0.40%
143 TERCONAZOLE	VAGINAL CREAM	0.80%
144 THEOPHYLLINE ER	TABLET	100MG
144 THEOPHYLLINE ER	TABLET	200MG
144 THEOPHYLLINE ER	TABLET	300MG
144 THEOPHYLLINE ER	TABLET	400MG
144 THEOPHYLLINE ER	TABLET	450MG
144 THEOPHYLLINE ER	TABLET	600MG
145 TIMOLOL MALEATE	GEL	0.25%
145 TIMOLOL MALEATE	GEL	0.50%
146 TIZANIDINE HCL	TABLET	2MG
146 TIZANIDINE HCL	TABLET	4MG
147 TOBRAMYCIN	SOLUTION	300MG/5ML
148 TOBRAMYCIN/DEXAMETHASONE	SOLUTION	0.3;0.1%
149 TOLMETIN SODIUM	CAPSULE	400MG
150 TOLTERODINE TARTRATE	TABLET	1MG
150 TOLTERODINE TARTRATE	TABLET	2MG
150 TOLTERODINE TARTRATE ER	CAPSULE	2MG
150 TOLTERODINE TARTRATE ER	CAPSULE	4MG
151 TRAZODONE HCL	TABLET	100MG
152 TRIAMCINOLONE ACETONIDE	CREAM	0.03%
152 TRIAMCINOLONE ACETONIDE	CREAM	0.10%
152 TRIAMCINOLONE ACETONIDE	CREAM	0.50%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.03%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.10%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.50%
153 TRIAMTERENE/HCTZ	CAPSULE	37.5MG;25MG
153 TRIAMTERENE/HCTZ	TABLET	37.5MG;25MG
153 TRIAMTERENE/HCTZ	TABLET	75MG;50MG
154 TRIFLUOPERAZINE HCL	TABLET	10MG
154 TRIFLUOPERAZINE HCL	TABLET	1MG
154 TRIFLUOPERAZINE HCL	TABLET	2MG
154 TRIFLUOPERAZINE HCL	TABLET	5MG
155 URSODIOL	CAPSULE	300MG
156 VALSARTAN HCTZ	TABLET	160MG;12.5MG
156 VALSARTAN HCTZ	TABLET	160MG;25MG
156 VALSARTAN HCTZ	TABLET	320MG;12.5MG

156 VALSARTAN HCTZ	TABLET	320MG;25MG
156 VALSARTAN HCTZ	TABLET	80MG;12.5MG
157 VERAPAMIL	TABLET	120MG
157 VERAPAMIL	TABLET	80MG
157 VERAPAMIL SR	CAPSULE	120MG
157 VERAPAMIL SR	CAPSULE	180MG
157 VERAPAMIL SR	CAPSULE	240MG
158 WARFARIN SODIUM	TABLET	10MG
158 WARFARIN SODIUM	TABLET	1MG
158 WARFARIN SODIUM	TABLET	2.5MG
158 WARFARIN SODIUM	TABLET	2MG
158 WARFARIN SODIUM	TABLET	3MG
158 WARFARIN SODIUM	TABLET	4MG
158 WARFARIN SODIUM	TABLET	5MG
158 WARFARIN SODIUM	TABLET	6MG
158 WARFARIN SODIUM	TABLET	7.5MG
159 ZOLEDRONIC ACID	IV CONCENTRATE	4MG/5ML
159 ZOLEDRONIC ACID	IV SOLUTION	5MG/100ML

APPENDIX B: NAMED DEFENDANTS

- 1. Actavis Holdco U.S., Inc.
- 2. Actavis Pharma, Inc.
- 3. Actavis Elizabeth, LLC
- 4. Akorn Inc.
- 5. Alvogen Inc.
- 6. Amneal Pharmaceuticals, Inc.
- 7. Amneal Pharmaceuticals, LLC
- 8. Apotex Corp.
- 9. Ascend Laboratories, LLC
- 10. Aurobindo Pharma USA, Inc.
- 11. Bausch Health Americas, Inc.
- 12. Bausch Health US, LLC
- 13. Breckenridge Pharmaceutical, Inc.
- 14. Camber Pharmaceuticals Inc.
- 15. Citron Pharma LLC
- 16. Dava Pharmaceuticals, LLC
- 17. Dr. Reddy's Laboratories, Inc.
- 18. Epic Pharma, LLC
- 19. Fougera Pharmaceuticals Inc.
- 20. Generics Bidco I LLC
- 21. Glenmark Pharmaceuticals Inc., USA.
- 22. Greenstone LLC
- 23. G&W Laboratories, Inc.
- 24. Heritage Pharmaceuticals, Inc.
- 25. Hikma Labs, Inc.
- 26. Hikma Pharmaceuticals USA, Inc.
- 27. Hi-Tech Pharmacal Co., Inc.
- 28. Impax Laboratories, Inc.
- 29. Impax Laboratories, LLC
- 30. Jubilant Cadista Pharmaceuticals Inc.
- 31. Lannett Company, Inc.
- 32. Lupin Pharmaceuticals, Inc.
- 33. Mallinckrodt Inc.
- 34. Mayne Pharma Inc.
- 35. Morton Grove Pharmaceuticals, Inc.
- 36. Mylan Inc.
- 37. Mylan Pharmaceuticals Inc.
- 38. Oceanside Pharmaceuticals, Inc.
- 39. Par Pharmaceutical Companies, Inc.
- 40. Par Pharmaceutical, Inc.
- 41. Perrigo New York, Inc.
- 42. Pfizer, Inc.
- 43. Pliva, Inc.
- 44. Sandoz, Inc.
- 45. Sun Pharmaceutical Industries, Inc.
- 46. Taro Pharmaceuticals U.S.A., Inc.
- 47. Teligent Inc.
- 48. Teva Pharmaceuticals USA, Inc.
- 49. Torrent Pharma Inc.
- 50. UDL Laboratories, Inc.
- 51. Upsher-Smith Laboratories, Inc.
- 52. Valeant Pharmaceuticals International
- 53. Valeant Pharmaceuticals North America LLC
- 54. Versapharm, Inc.
- 55. West-Ward Columbus, Inc.
- 56. West-Ward Pharmaceuticals Corp.
- 57. Wockhardt USA LLC
- 58. Zydus Pharmaceuticals (USA), Inc.

EXHIBIT B



Did You Purchase Certain Named
GENERIC
PHARMACEUTICAL
DRUGS
DIRECTLY
from certain
pharmaceutical
manufacturers?

YOUR RIGHTS MAY BE
AFFECTED BY A
PROPOSED CLASS
ACTION SETTLEMENT

LEARN MORE →

GenericDrugsDirectPurchaserSettlement.com

EXHIBIT C

ADVERTISEMENT

The Marketplace

To advertise: 800-366-3975 or WSJ.com/classifieds

CLASS ACTIONS

If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.*A federal court authorized this notice. This is not a solicitation from a lawyer.*

What is the lawsuit about? Two proposed settlements (the "Settlements") have been reached in a class action lawsuit ("the Lawsuit"), which alleges that Sun Pharmaceutical Industries, Inc. and its affiliates, Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc. (collectively "Settling Defendants") violated the federal antitrust laws by conspiring with other generic drug manufacturers to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the "Named Generic Drugs"), causing direct purchasers of the Named Generic Drugs to pay more than they should have. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing.

Who is included? The Court certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Settlement Agreements listing the Named Generic Drugs and Defendants are available on the settlement website: GenericDrugsDirectPurchaserSettlement.com. The Settlement Agreements also are on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106 in the case *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724.

What do the Settlements provide? The proposed Settlements provide for the following payments by Settling Defendants: (1) \$17,357,000 payment by Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc. and (2) \$67,643,000 payment by Taro Pharmaceuticals U.S.A., Inc. These payments (collectively \$85,000,000) will comprise the total "Settlement Fund." The Settlement Fund may be reduced by up to \$10 million or increased to a maximum of \$105 million under certain circumstances as explained in the Settlement Agreements. In addition, the attorneys who have worked on the Lawsuit for the Settlement Class will seek Court approval to pay expenses, attorneys' fees of up to one-third of the Settlement Fund, including interest, after expenses (and service awards) are deducted, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. Any motion for expenses and service awards and to set aside one-third of the remaining Settlement Fund (plus accrued interest) for payment of attorneys' fees will be posted on the settlement website GenericDrugsDirectPurchaserSettlement.com once they are filed on August 9, 2022. Settlement Class Counsel will file a motion for an award of fees at a later appropriate time.

The calculations of the dollar amount that each Settlement Class Member that submits a Claim Form will be paid from the Settlement Fund is set forth in the Plan of Allocation, which also is available on GenericDrugsDirectPurchaserSettlement.com.

What are your options? If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlements as described in this notice, if the Settlements are approved. However, you will need to complete, sign, and return the Claim Form (once it is sent to you) in order to obtain a payment. It is anticipated that Defendants' sales data will be used to calculate Settlement Class Members' eligible purchases and *pro rata* share of the Net Settlement Fund, but if such data is not available from Defendants then you may be required to submit data showing your eligible purchases. We do not know when the Claim Forms will be mailed. You should check GenericDrugsDirectPurchaserSettlement.com for information regarding timing. If you did not receive a Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation – Direct Purchasers*, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217, or send an email to info@GenericDrugsDirectPurchaserSettlement.com, or call 877-315-0583. You may be required to submit proof of a qualifying purchase to establish that you are a member of the Settlement Class. Claimants may also be required to submit purchase data as part of the claims process. As a Settlement Class Member, unless you opt out of the Settlements, you will be bound by all orders and judgments of the Court.

In addition, you may request exclusion from (or opt out of) the Settlements and may object to the Settlements if you do not opt out. Instructions for opting out or objecting can be found in the publicly-available case file and website, as described above. You must mail your request to opt out or your objection by September 23, 2022. The Court will hold a Fairness Hearing on **December 13, 2022 at 1:30 p.m. EST** to decide whether to approve the Settlements and any requests for fees, expenses, and service awards for the class representatives. The Court will also consider a Plan of Allocation for distributing the Settlement Fund to Settlement Class Members. If there are objections, the Court will consider them at the hearing. You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may hire your own attorney to appear in Court for you at your own expense.

For more information: Go to the website: GenericDrugsDirectPurchaserSettlement.com or call 877-315-0583 for more information on the Settlements, the Lawsuit, and your potential rights and options related to the Settlements. The website includes, for example, a list of the generic drugs that you would have had to purchase and a list of the generic drug manufacturers that you would have had to purchase *directly* from in order to be eligible for a payment.

EXHIBIT D



Direct Purchaser Plaintiffs Announce Settlements in *In Re Generic Pharmaceutical Pricing Antitrust Litigation*.

NastLaw LLC Announces if you purchased certain named generic pharmaceutical drugs *directly* from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.

A federal court authorized this notice. This is not a solicitation from a lawyer.

June 24, 2022 05:16 PM Eastern Daylight Time

PHILADELPHIA--(BUSINESS WIRE)--What is the lawsuit about? Two proposed settlements (the "Settlements") have been reached in a class action lawsuit ("the Lawsuit"), which alleges that Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc. (collectively "Settling Defendants") violated the federal antitrust laws by conspiring with other generic drug manufacturers to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the "Named Generic Drugs"), causing direct purchasers of the Named Generic Drugs to pay more than they should have. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing.

Who is included? The Court certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Settlement Agreements listing the Named Generic Drugs and Defendants are available on the settlement website: GenericDrugsDirectPurchaserSettlement.com. The Settlement Agreements also are on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106 in the case *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724.

What do the Settlements provide? The proposed Settlements provide for the following payments by Settling Defendants: (1) \$17,357,000 payment by Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc. and (2) \$67,643,000 payment by Taro Pharmaceuticals U.S.A., Inc. These payments (collectively \$85,000,000) will comprise the total "Settlement Fund." The Settlement Fund may be reduced by up to \$10 million or increased to a maximum of \$105 million under certain circumstances as explained in the Settlement Agreements. In addition, the attorneys who have worked on the Lawsuit for the Settlement Class will seek Court approval to pay expenses, attorneys' fees of up to one-third of the Settlement Fund, including interest, after expenses (and service awards) are deducted, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. Any motion for expenses and service awards and to set aside one-third of the remaining Settlement Fund (plus accrued interest) for payment of attorneys' fees will be posted on the settlement website GenericDrugsDirectPurchaserSettlement.com once they are filed on August 9, 2022. Settlement Class Counsel will file a motion for an award of fees at a later appropriate time.

The calculations of the dollar amount that each Settlement Class Member that submits a Claim Form will be paid from the Settlement Fund is set forth in the Plan of Allocation, which also is available on GenericDrugsDirectPurchaserSettlement.com.

What are your options? If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlements as described in this notice, if the Settlements are approved. However, you will need to complete, sign, and return the Claim Form (once it is sent to you) in order to obtain a payment. It is anticipated that Defendants' sales data will be used to calculate Settlement Class Members' eligible purchases and *pro rata* share of the Net Settlement Fund, but if such data is not available from Defendants then you may be required to submit data showing your eligible purchases. We do not know when the Claim Forms will be mailed. You should check GenericDrugsDirectPurchaserSettlement.com for information regarding timing. If you *did not* receive a Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217, or send an email to info@GenericDrugsDirectPurchaserSettlement.com, or call 877-315-0583. You may be required to submit proof of a qualifying purchase to establish that you are a member of the Settlement Class. Claimants may also be required to submit purchase data as part of the claims process. As a Settlement Class Member, unless you opt out of the Settlements, you will be bound by all orders and judgments of the Court.

In addition, you may request exclusion from (or opt out of) the Settlements and may object to the Settlements if you do not opt out. Instructions for opting out or objecting can be found in the publicly-available case file and website, as described above. You must mail your request to opt out or your objection by September 23, 2022. The Court will hold a Fairness Hearing on December 13, 2022 at 1:30 p.m. EST to decide whether to approve the Settlements and any requests for fees, expenses, and service awards for the class representatives. The Court will also consider a Plan of Allocation for distributing the Settlement Fund to Settlement Class Members. If there are objections, the Court will consider them at the hearing. You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may hire your own attorney to appear in Court for

For more information: Go to the website: GenericDrugsDirectPurchaserSettlement.com or call 877-315-0583 for more information on the Settlements, the Lawsuit, and your potential rights and options related to the Settlements. The website includes, for example, a list of the generic drugs that you would have had to purchase and a list of the generic drug manufacturers that you would have had to purchase *directly* from in order to be eligible for a payment.

Contacts

Dianne M. Nast, Esq.

Joseph N. Roda, Esq.

(215) 923-9300

EXHIBIT E

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

1. Accredo Health Group, Inc.
2. Acme Markets
3. Albany Area Primary Health Care, Inc.
4. Albertson's, Inc.
5. Albertsons
6. Albertsons Companies LLC
7. Albertsons Companies, Inc.
8. Albertsons LLC
9. Albertsons Market
10. Alliance
11. Alliance BMP
12. Alliance Boots
13. Alliance Healthcare
14. Alliance Rx Walgreens Prime Pharmacy
15. Alliance Santé
16. Alliance UniChem
17. Allina Health System
18. American Drug Stores
19. American Stores Company
20. Andronico's
21. Andronico's Community Markets
22. Augusta Health Care, Inc., d/b/a Augusta Health
23. Avera Health
24. Baker's
25. Balducci's Food Lover's Markets
26. Baptist Health
27. Baxter County Regional Hospital, Inc., d/b/a Baxter Regional Medical Center
28. Baystate Health, Inc.
29. Beaufort-Jasper-Hampton Comprehensive Health Services, Inc.
30. Berkshire Health Systems
31. Billings Clinic
32. Bowen Development
33. Bravo Health Mid-Atlantic Inc.
34. Bravo Health Pennsylvania Inc.
35. Broad Top Area Medical Center, Inc.
36. Burlington Drug
37. Burlington Drug Company
38. Burrells
39. Burrells Limited

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

40. Butler Health System
41. Cape Cod Healthcare, Inc.
42. Care New England
43. CaroMont Health, Inc.
44. Carr-Gottstein Foods Co.
45. CentraCare Health
46. Central Market
47. Central Texas Community Health Centers, d/b/a CommUnityCare
48. Children's Hospital of Philadelphia
49. Cigna Corporation
50. Cigna Health and Life Insurance Company
51. Cigna HealthCare of Arizona, Inc.
52. Cigna HealthCare of California, Inc.
53. Cigna HealthCare of Colorado, Inc.
54. Cigna HealthCare of Connecticut, Inc.
55. Cigna HealthCare of Florida, Inc.
56. Cigna HealthCare of Georgia, Inc.
57. Cigna HealthCare of Illinois, Inc.
58. Cigna HealthCare of Indiana, Inc.
59. Cigna HealthCare of Maine, Inc.
60. Cigna HealthCare of Massachusetts, Inc.
61. Cigna HealthCare of Mid-Atlantic, Inc.
62. Cigna HealthCare of New Hampshire, Inc.
63. Cigna HealthCare of New Jersey, Inc.
64. Cigna HealthCare of North Carolina, Inc.
65. Cigna HealthCare of Pennsylvania, Inc.
66. Cigna HealthCare of South Carolina, Inc.
67. Cigna HealthCare of St. Louis, Inc.
68. Cigna HealthCare of Tennessee, Inc.
69. Cigna HealthCare of Texas, Inc.
70. Cigna HealthCare of Utah, Inc.
71. City Market
72. Collier Health Services, Inc., d/b/a Healthcare Network
73. Community Health Center of Snohomish County
74. Company Amigos United
75. Confluence Health
76. Conway Regional Health System
77. Cook County Hospital District, d/b/a North Shore Health
78. Cook Hospital

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

79. Copps Food Center
80. Crusaders Central Clinic Association
81. CuraScript, Inc.
82. CVS Health Corp.
83. CVS Pharmacy, Inc.
84. Cystic Fibrosis Services
85. Cystic Fibrosis Services Inc.
86. Cystic Fibrosis Services LLC
87. Dallas County Medical Center
88. DCH Health System
89. Delta Memorial Hospital
90. Dillon
91. Dillon Companies, Inc.
92. Dominick's
93. Dominick's Finer Foods, LLC
94. Douglas County Hospital, d/b/a Alomere Health
95. Drew Memorial Hospital, Inc., d/b/a Drew Memorial Health System
96. Duane Reade
97. Duane Reade, Inc.
98. Duval Pharmacy
99. East Boston Neighborhood Health Center
100. Ely-Bloomenson Community Hospital
101. Erie Family Health Centers
102. ESI Mail Pharmacy Service, Inc.
103. Essentia Health
104. Evangelical Community Hospital
105. Excela Health
106. Express Scripts Holding Company
107. Express Scripts Pharmaceutical Procurement LLC
108. Express Scripts Pharmacy, Inc.
109. Express Scripts, Inc.
110. Extreme Value
111. Extreme Value Centers
112. Fairview Health Services
113. FMJ, Inc.
114. Food 4 Less
115. Food 4 Less Holdings, Inc.
116. Foods Pavilion
117. Fred Meyer

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

118. Fred Meyer Jewelers, Inc.
119. Fred Meyer Stores, Inc.
120. Fred Meyer, Inc.
121. Fry's
122. Fulton County Medical Center
123. Genuardi's
124. Genuardi's Family Markets LP
125. Gerbes
126. Gillette Children's Specialty Healthcare
127. Glacial Ridge Health System
128. Glencoe Regional Health Services, d/b/a Glencoe Regional Health
129. Globe Stores
130. Granby Pharmacy, Inc., d/b/a Center Pharmacy
131. Great Lakes Bay Health Centers
132. Great Salt Plains Health Center, Inc.
133. Greater Lawrence Family Health Center
134. Green Hills Insurance
135. Guthrie Hospitals
136. H.E. Butt Grocery Company
137. H.E. Butt Grocery Company L.P.
138. Haggen
139. Haggen Food & Pharmacy
140. Happy Harry's
141. Happy Harry's Discount Drug Stores, Inc.
142. Happy Harry's Inc.
143. Harris Teeter
144. Harris Teeter, Inc.
145. Harris Teeter, LLC
146. HC Pharmacy Central, Inc.
147. Health Partners of Western Ohio
148. HealthPoint
149. HealthSpring Life & Health Insurance Company, Inc.
150. HealthSpring of Florida, Inc.
151. HealthSpring Pharmacy of Tennessee, LLC
152. HealthSpring Pharmacy Services, LLC
153. Healthy Options, Inc.
154. H-E-B
155. Hennepin Healthcare System, Inc.
156. Home Chef

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

- 157. Humana Inc.
- 158. Humana Pharmacy, Inc.
- 159. Infinity Infusion
- 160. International Community Health Services
- 161. J M Smith
- 162. J M Smith Corporation
- 163. Jay C Food Stores
- 164. Jerseymaid Milk Products
- 165. Jewel Food Stores
- 166. Jewel Foods
- 167. Jewel Foods, Inc.
- 168. Jewel-Osco Pharmacy
- 169. Junior Food Stores of West Florida, Inc.
- 170. Kessel
- 171. Kessel Food Markets, Inc.
- 172. King Soopers
- 173. Kings Food Markets
- 174. Kiosk Medicine Kentucky, LLC
- 175. Kittson Healthcare
- 176. Kootenai Hospital District, an Idaho Public Hospital District, d/b/a Kootenai Health
- 177. KRGP Inc.
- 178. Kroger
- 179. Kroger Limited Partnership I
- 180. Kroger Limited Partnership II
- 181. Kroger Texas L.P.
- 182. Lake Region Healthcare
- 183. Lakewood Health System
- 184. Lawrence Brothers
- 185. Lawrence Brothers Co.
- 186. Lawrence Brothers Pharmacy
- 187. Lehigh Valley Health System
- 188. LifeCare Medical Center
- 189. Lifespan Corporation
- 190. Logan Health
- 191. Longview Wellness Center, Inc., d/b/a Wellness Pointe
- 192. Lucerne Foods, Inc.
- 193. Lucky Stores (Utah locations)
- 194. Lutheran Charity Association, d/b/a Jamestown Regional Medical Center

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

195. Lynnfield Compounding Center, Inc.
196. Lynnfield Drug, Inc.
197. Madelia Health
198. Madison Health (formerly Madison Memorial Hospital)
199. Madison Healthcare Services, d/b/a Madison Hospital
200. Main Line Health
201. Marana Health Center, Inc.
202. Mariano's Fresh Market
203. Market Street
204. Mary Rutan Hospital
205. Mass General Brigham Incorporated
206. Matthews Property 1, LLC
207. Mayo Clinic (requested exclusion from the Taro settlement only)
208. May's Drug Stores
209. May's Drug Stores, Inc.
210. Medco Containment Insurance Company of NY
211. Medco Containment Life Insurance Company
212. MedCura Health Inc. (formerly Oakhurst Medical Centers, Inc.)
213. Medicenter
214. Med-X
215. Med-X Corporation
216. Meeker Memorial Hospital and Clinic
217. Memorial Hospital of Laramie County, d/b/a Cheyenne Regional Medical Center
218. Memorial Hospital of Sweetwater County
219. Memorial Sloan Kettering Cancer Center
220. Metro Market
221. Middlesex Health
222. Millcreek Community Hospital
223. Mille Lacs Health System
224. Montefiore Medical Center
225. Mount Nittany Health System
226. Murray County Medical Center
227. New Albertson's Inc.
228. New Albertson's L.P.
229. NewYork-Presbyterian
230. North Memorial Health
231. North Olympic Healthcare Network
232. North Valley Health Center

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

- 233. Northern Itasca Hospital District, d/b/a Bigfork Valley
- 234. Northfield Hospitals + Clinics
- 235. Novant Health, Inc.
- 236. Nuvance Health
- 237. NYU Langone Hospitals
- 238. Ochsner Health
- 239. Olmsted Medical
- 240. Omnicare
- 241. OptumRx Group Holdings, Inc.
- 242. OptumRx Holdings, LLC
- 243. OptumRx, Inc.
- 244. Ortonville Area Health Services
- 245. Osco Drugs
- 246. Overtake Hospital Medical Center
- 247. Owen's
- 248. Owen's Supermarket
- 249. Ozarks Community Hospital
- 250. Pak 'N Sav
- 251. Paul's Market
- 252. Pavilions Place Randall's
- 253. Pay Less Super Markets
- 254. PeaceHealth
- 255. Peak Vista Community Health Centers
- 256. Penn Highlands Healthcare
- 257. Perham Health
- 258. Peyton's
- 259. Peyton's Fountain
- 260. Peyton's Mid-South Company
- 261. Peyton's Northern
- 262. Peyton's Phoenix
- 263. Peyton's-Southeastern, Inc.
- 264. Pick 'n Save
- 265. Pikeville Medical Center, Inc.
- 266. Postal Prescription Services
- 267. Prime Therapeutics Specialty Pharmacy
- 268. Prime Therapeutics Specialty Pharmacy LLC
- 269. Priority Healthcare Corporation
- 270. Priority Healthcare Distribution, Inc.
- 271. Providence St. Joseph Health

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

- 272. Pueblo Community Health Center, Inc.
- 273. QFC
- 274. Raley's of New Mexico
- 275. Ralphs
- 276. Ralphs Grocery Company
- 277. Randall's Food & Drugs LP
- 278. Ridgeview Medical Center
- 279. Rite Aid Corporation
- 280. Rite Aid Hdqtrs. Corp.
- 281. River's Edge Hospital
- 282. Riverview Healthcare Association
- 283. Riviera Brands
- 284. Roanoke Chowan Community Health Center
- 285. Roundy's Inc.
- 286. Ruler Foods
- 287. Rutherford County Primary Care Clinic, Inc., d/b/a Primary Care & Hope Clinic
- 288. RWJBarnabas Health
- 289. S&W Pharmacy
- 290. S&W Pharmacy, Inc.
- 291. Safeway
- 292. Safeway Food & Drug
- 293. Safeway Inc.
- 294. Sanford Health
- 295. Sav-On Drug
- 296. Scott's Foods
- 297. Scott's Pharmacy
- 298. Select Medical
- 299. Shands Jacksonville Medical Center, Inc.
- 300. Shands Teaching Hospital and Clinics, Inc.
- 301. Shasta Community Health Center
- 302. Shaw's Supermarkets, Inc.
- 303. Shawnee Health Service and Development Corporation
- 304. Shop-Rite, LLC
- 305. Simon David
- 306. Sleepy Eye Medical Center
- 307. Smith Drug
- 308. Smith Drug Company
- 309. Smith's Food & Drug Centers, Inc.

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

- 310. Smith's
- 311. South Big Horn County Hospital District, d/b/a Three Rivers Health
- 312. Specialty Products Acquisitions, LLC
- 313. St. Clair Health Corporation
- 314. St. Luke's Hospital of Duluth
- 315. St. Luke's University Health Network
- 316. St. Thomas Community Health Center
- 317. Stamford Health, Inc.
- 318. Star Market
- 319. Stigler Health & Wellness Center, Inc.
- 320. Sunrise R&D Holdings, LLC
- 321. Sunrise Technology LLC
- 322. Super D. Drugs Acquisition Co.
- 323. Super Saver Foods
- 324. Superior
- 325. Superior Acquisitions Limited
- 326. Superior Holdings Limited
- 327. Swift County-Benson Health Services
- 328. Syringa Hospital Districts
- 329. Tel-Drug of Pennsylvania, LLC
- 330. Tel-Drug, Inc.
- 331. The Chautauqua Center, Inc.
- 332. The Children's Hospital Corporation, d/b/a Boston Children's Hospital
- 333. The Kroger Co.
- 334. The Kroger Co. of Michigan
- 335. The Mount Sinai Hospitals Group, Inc.
- 336. The Vons Companies, Inc.
- 337. Thomas Jefferson University
- 338. TLC Corporate Services LLC
- 339. Tom Thumb Food & Drugs
- 340. Tri-Area Community Health
- 341. Tri-County Health Care
- 342. Trinity Home Care
- 343. UC Health
- 344. UHS of Delaware, Inc.
- 345. UM Health
- 346. UMass Memorial Health
- 347. United Express
- 348. United HealthCare Services, Inc.

In re: Generic Pharmaceuticals Pricing Antitrust Litigation,
Case No: 2:16-MD-02724 (E.D. Pa.)

Exclusion Requests

- 349. United Hospital District, Inc.
- 350. United Supermarkets
- 351. United Supermarkets, LLC
- 352. University Health Systems of Eastern Carolina, Inc., d/b/a ECU Health
- 353. Upham's Corner Health Committee, Inc.
- 354. UPMC (University of Pittsburgh Medical Center)
- 355. USA Drug
- 356. USA/Super D Franchising
- 357. Valley Health
- 358. Valor Health
- 359. Vineyard Scripts
- 360. Vons
- 361. Vons Grocery Company
- 362. WakeMed Health & Hospital
- 363. Walgreen
- 364. Walgreen Co.
- 365. Walgreen Company
- 366. Walgreens
- 367. Welia Health
- 368. Wellpath LLC
- 369. West Tennessee Healthcare
- 370. White River Health System, Inc., d/b/a White River Medical Center
- 371. Winona Health Services